Peter Libby Selected Research

canakinumab

10/2022	Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
10/2020	Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
1/2020	Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
1/2020	Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
1/2020	Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS.
1/2019	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
1/2019	Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology.
1/2019	Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
1/2019	Novel Antiatherosclerotic Therapies.
1/2019	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Libby Research Topics

Disease

157	Atherosclerosis 12/2022 - 01/2002
115	Inflammation (Inflammations) 10/2022 - 01/2002
71	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2002
55	Myocardial Infarction 10/2022 - 02/2002
51	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 09/2002
46	Thrombosis (Thrombus) 10/2022 - 05/2002
23	Coronary Artery Disease (Coronary Atherosclerosis) 10/2022 - 12/2002
22	Acute Coronary Syndrome 03/2022 - 09/2003
20	Stroke (Strokes) 11/2021 - 05/2002
20	Abdominal Aortic Aneurysm 01/2021 - 11/2004
14	Rupture 01/2021 - 10/2002
12	Coronary Disease (Coronary Heart Disease) 12/2020 - 07/2004
12	Obesity 01/2019 - 03/2006
11	Unstable Angina 10/2018 - 09/2003
10	Hypertension (High Blood Pressure) 09/2022 - 05/2002
10	COVID-19 07/2022 - 01/2020
10	Neoplasms (Cancer) 06/2022 - 11/2008
10	Infections 01/2021 - 01/2002
9	Rheumatoid Arthritis 09/2022 - 04/2009
9	Infarction (Infarctions) 01/2019 - 02/2002
8	Heart Failure 09/2022 - 04/2014
8	Fibrosis (Cirrhosis) 01/2021 - 03/2007
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2019 - 02/2006
7	Dyslipidemias (Dyslipidemia) 10/2021 - 11/2004
7	Type 2 Diabetes Mellitus (MODY) 01/2019 - 06/2003
7	Disease Progression 01/2018 - 04/2006
6	Osteoarthritis 09/2022 - 04/2009
6	Insulin Resistance 01/2022 - 03/2004
6	Chronic Renal Insufficiency 01/2021 - 04/2009
6	Vascular Diseases (Vascular Disease) 11/2020 - 12/2002
6	Diabetes Mellitus 01/2020 - 05/2002
6	Aneurysm (Aneurysms) 12/2017 - 05/2005
5	Arthritis (Polyarthritis) 09/2022 - 09/2002
5	Calcinosis 01/2020 - 06/2013
5	Atrial Fibrillation 01/2020 - 07/2011
5	Myocardial Ischemia (Ischemic Heart Diseases) 02/2012 - 09/2003
4	Hyperglycemia 07/2022 - 05/2002
4	Hypoxia (Hypoxemia) 12/2020 - 08/2011

Drug/Important Bio-Agent (IBA)

57	LipidsIBA 01/2022 - 01/2002
52	CytokinesIBA 10/2022 - 01/2002
47	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2021 - 09/2002
36	CholesterolIBA 10/2022 - 05/2002
33	C-Reactive ProteinIBA 01/2022 - 03/2002
31	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2005
26	Apolipoproteins E (ApoE)IBA 10/2022 - 02/2005
21	oxidized low density lipoproteinIBA 01/2022 - 09/2002
20	Proteins (Proteins, Gene)FDA Link 06/2022 - 09/2002
20	Interleukin-6 (Interleukin 6)IBA 01/2022 - 09/2003
20	Atorvastatin (Lipitor)FDA Link 01/2020 - 09/2003
19	canakinumab FDA Link 10/2022 - 10/2011
19	LDL CholesterolIBA 03/2022 - 06/2003
19	CollagenIBA 01/2021 - 02/2002
18	Rosuvastatin Calcium (Crestor)FDA Link 08/2017 - 03/2004
16	Lipoproteins (Lipoprotein)IBA 01/2022 - 08/2002
15	InterleukinsIBA 01/2022 - 01/2002
15	Matrix Metalloproteinases (MMPs)IBA 11/2021 - 01/2002
15	Peptide Hydrolases (Proteases)FDA Link 01/2019 - 03/2003
15	CD40 Ligand (CD40L)IBA 11/2011 - 12/2002
14	ApolipoproteinsIBA 05/2016 - 02/2005
13	HDL CholesterolIBA 10/2021 - 06/2003
11	InflammasomesIBA 10/2022 - 10/2014
11	Biological ProductsIBA 07/2022 - 04/2006
11	Triglycerides (Triacylglycerol)IBA 01/2022 - 06/2003
11	Thromboplastin (Tissue Factor)IBA 01/2021 - 07/2002
11	LDL Receptors (LDL Receptor)IBA 11/2020 - 01/2002
11	ChemokinesIBA 01/2019 - 01/2002
10	Angiotensin IIIBA 01/2021 - 03/2009
10	Cysteine Proteases (Cysteine Protease)IBA 01/2018 - 08/2004
9	Monoclonal AntibodiesIBA 10/2022 - 12/2012
9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 08/2007
9	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 11/2004
9	EnzymesIBA 01/2019 - 07/2004
9	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2015 - 09/2002
8	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 07/2022 - 11/2012
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 10/2002
8	ElastinIBA 05/2016 - 04/2003
8	AdiponectinIBA 02/2013 - 03/2006
7	Ibuprofen (Motrin)FDA LinkGeneric 09/2022 - 04/2009
7	Naproxen (Naprosyn)FDA LinkGeneric 09/2022 - 04/2009
7	Celecoxib (Celebrex)FDA Link 09/2022 - 04/2009
7	Immunoglobulin E (IgE)IBA 01/2020 - 09/2011
7	Interleukin-18 (Interleukin 18)IBA 01/2020 - 01/2002
7	CathepsinsIBA 09/2019 - 04/2007
7	Collagenases (Collagenase)FDA Link 06/2014 - 02/2002
6	InterferonsIBA 12/2017 - 01/2002
6	Messenger RNA (mRNA)IBA 06/2015 - 05/2006
5	Cathepsin LIBA 01/2020 - 02/2006
5	Cathepsin KIBA 01/2019 - 05/2007
5	CalciumIBA 01/2018 - 09/2007
5	cathepsin SIBA 04/2015 - 03/2003
5	Interferon-gamma (Interferon, gamma)IBA 08/2009 - 05/2005
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 09/2022 - 04/2009
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2021 - 04/2002
4	Small Interfering RNA (siRNA)IBA 01/2021 - 04/2014
4	LigandsIBA 01/2021 - 12/2002
4	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 10/2009
4	Interleukin-1 (Interleukin 1)IBA 01/2021 - 01/2016
4	Pharmaceutical PreparationsIBA 07/2020 - 09/2002

Therapy/Procedure

79	Therapeutics 10/2022 - 01/2002
5	Secondary Prevention 01/2019 - 05/2007